Results 141 to 150 of about 107,610 (251)

Benign by design: A paradigm shift in cosmetic ingredient development

International Journal of Cosmetic Science, EarlyView.
Benign by design strategies enable the creation of biodegradable cosmetic ingredients, reducing environmental persistence while maintaining the intended biological activity. This work compiles design rules and tools to guide the development of more sustainable molecules for the cosmetics industry.
Sandra Mota, Klaus Kümmerer, Isabel Martins de Almeida, Emília Sousa   +3 more
wiley   +1 more source

Impact of <i>UGT1A1*28</i> polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial. [PDF]

Future Oncol
Abdelrahim M, Khan G, Hatoum H, Zervoudakis A, Dayyani F, Zhang L, Li J, Maxwell F, O'Reilly EM, Wainberg ZA, Bullock A.   +10 more
europepmc   +1 more source

Comparison of pharmacogenomic guidance in Australian prescribing resources and international pharmacogenomic guidelines

Internal Medicine Journal, EarlyView.
Abstract Background Pharmacogenomic‐guided medication management optimises drug therapy to enhance patient outcomes. Despite clinical utility, implementation in Australia remains limited, partly due to the lack of clear and consistent guidance. Aim This study evaluated the presence and consistency of pharmacogenomic testing indication categories and ...
Ruby Soueid, Jackson L. A. Thomas, Luke B. Hesson, Stephen Hughes, Sophie L. Stocker   +4 more
wiley   +1 more source

Metronomic Capecitabine Triggers Ferroptosis in Hepatocellular Carcinoma Cells Through Inhibition of TYMS. [PDF]

Cancer Med
Yang R, Chang Y, Feng Z, Yang J, Sun Q, Wang H, Kong D, Duan J, Chen S, Cao L, Ren J, Yoshida S, Wang Z, Zheng H.   +13 more
europepmc   +1 more source

International Dermoscopy Society consensus recommendations for the management of lentigo maligna

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Lentigo maligna (LM) poses diagnostic and therapeutic challenges amid rising incidence and limited high‐quality evidence. This international expert consensus provides pragmatic, evidence‐based and expertise‐informed guidance on LM diagnosis and management.
Ana‐Maria Forsea, Riccardo Pampena, Bengu Nisa Akay, Zoe Apalla, Giuseppe Argenziano, Giulia Briatico, Ralph Braun, Horacio Cabo, Raul Cabrera, Cristina Carrera, Elisa Cinotti, Claudio Conforti, Enzo Errichetti, Gerardo Ferrara, Roberta Giuffrida, Stefania Guida, Pascale Guitera, Allan C. Halpern, Stephen Heyes, Rainer Hofmann‐Wellenhof, Angela M. Hong, Natalia Jaimes, Raimonds Karls, Harald Kittler, Teresa Kränke, Konstantinos Liopyris, Jie Liu, Caterina Longo, Josep Malvehy, Ashfaq A. Marghoob, Hoda Moneib, David Moreno Ramirez, Elvira Moscarella, Eduardo Nagore, Cristian Navarrete‐Dechent, John Paoli, Giovanni Pellacani, Ketty Peris, Susana Puig, Cliff Rosendahl, Lidia Rudnicka, Ahmed Sadek, Philippe Saiag, Gabriel Salerni, Alon Scope, Hans Peter Soyer, Michela V. Starace, Wilhelm Stolz, David L. Swanson, Luc Thomas, Philipp Tschandl, Iris Zalaudek, Aimilios Lallas   +52 more
wiley   +1 more source

HPV125‐induced generalized verrucosis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Sven Niklas Burmann, Ulrike Wieland, Finja Schweitzer, Frank Oellig, Mihael Skerlev, David Chromy, Alexander Kreuter, Steffi Silling   +7 more
wiley   +1 more source

Consensus on energy‐based devices for keloids and hypertrophic scars: A Latin American Delphi study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Latin American Delphi consensus supports a sequential, multimodal approach to keloids and hypertrophic scars: vascular devices for early/inflammatory lesions; intralesional triamcinolone + 5‐fluorouracil and other injectable drugs for active scars; fractional lasers for texture; and pigment‐targeting therapies for dyschromia, prioritizing safety in ...
Gisele Viana de Oliveira, Patricia Apt Druck, Alvaro Andres Luque Acevedo, Doris Hexsel, Gabriel Teixeira Gontijo, Gabriel Huerta Rivera, Luis Leobardo Velázquez‐Arenas, Flávia Alvim Sant Anna Addor, Fátima Agüero Zaputovich, Hector Leal‐Silva, Sebastian Leal‐Delgado, Carlos Echevarría Escribens, Kleber Danilo Ollague Murillo, Susana Misticone, Leandra D'orsi Metsavaht, Johnny de la Riva, Daniel Ricardo Galimberti, Silvia Karina Kaminsky Jedwab, Hector Ricardo Galván Garcia, Marcia Ramos e Silva, Mariana Rocha Andrade, Eugenio Reis‐Filho, Marcio Roberto Silva, George Krompouzos, Daniela Guzmán‐Sánchez   +24 more
wiley   +1 more source

Predictors of prolonged progression-free survival in patients with unresectable or recurrent pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid (NAPOLEON-2 study). [PDF]

Ther Adv Med Oncol
Kawaguchi Y, Hayashi K, Shimokawa M, Otsuka T, Nakazawa J, Shimokawa H, Shinohara Y, Koga F, Oza N, Oda H, Takeshita S, Arima S, Arita S, Nishikawa K, Otsu S, Taguchi H, Jikuya K, Sakai T, Ueda Y, Sakae T, Araki N, Sawase H, Ide Y, Kawahira M, Nio K, Shirakawa T, Mizuta T, Mitsugi K.   +27 more
europepmc   +1 more source

The Dual Face of Fusobacterium nucleatum in Cancer: Foe, Friend or Both?

Journal of Periodontal Research, EarlyView.
Fusobacterium nucleatum has established interactions with cancers in humans. However, contrary to a traditional view that these interactions are uniformly pro‐tumoural, recent evidence suggests a more nuanced role, where contact‐dependent and contact‐independent mechanisms may support either tumour progression or restriction depending on tumour site ...
Anjali Chander, Huile Lim, Gilad Bachrach, Miguel Reis Ferreira   +3 more
wiley   +1 more source

Finding ferritin footprints in 5-fluorouracil-induced cardiotoxicity. [PDF]

Cardiooncology
Ferri GM, Urina-Jassir M, Stanisic AV, Hensien JM, Lee G, Sullivan N, Siddiqi OK.   +6 more
europepmc   +1 more source